Profile data is unavailable for this security.
About the company
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
- Revenue in USD (TTM)0.00
- Net income in USD-460.47m
- Incorporated2020
- Employees355.00
- LocationCerevel Therapeutics Holdings Inc222 Jacobs Street, Suite 200CAMBRIDGE 02141United StatesUSA
- Phone+1 (212) 284-2300
- Fax+1 (302) 636-5454
- Websitehttps://www.cerevel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | 1.85bn | 205.05m | 6.46bn | 1.31k | 34.30 | 3.08 | 28.05 | 3.50 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.54bn | 645.00 | -- | 21.04 | -- | 23.17 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 6.55bn | 373.00 | 21.28 | 36.80 | 16.33 | 7.59 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.62bn | 411.00 | -- | 3.84 | -- | 1,450.77 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.70bn | 2.80k | 21.93 | 1.81 | 6.85 | 1.74 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.24bn | 610.00 | -- | 11.15 | -- | 14.08 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.34bn | 355.00 | -- | 12.97 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.84bn | 420.00 | 41.80 | -- | 33.15 | 4.25 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Roivant Sciences Ltd | 124.80m | 4.35bn | 7.85bn | 845.00 | 2.10 | 1.44 | 1.84 | 62.86 | 5.07 | 5.07 | 0.1571 | 7.40 | 0.026 | 0.8187 | 2.97 | 147,686.40 | 88.04 | -- | 103.92 | -- | 87.53 | -- | 3,390.53 | -- | 25.10 | -- | 0.0642 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 7.89bn | 254.00 | -- | 3.97 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Exact Sciences Corp | 2.53bn | -240.23m | 8.24bn | 6.50k | -- | 2.62 | -- | 3.25 | -1.32 | -1.32 | 13.93 | 17.04 | 0.3998 | 5.28 | 11.96 | 389,975.40 | -3.79 | -9.71 | -4.13 | -10.60 | 73.67 | 74.10 | -9.48 | -28.21 | 1.45 | -- | 0.4323 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Repligen Corp | 607.45m | 14.84m | 8.30bn | 1.78k | 588.46 | 4.21 | 98.26 | 13.66 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| KBR Inc | 7.07bn | -258.00m | 8.46bn | 34.00k | -- | 6.02 | -- | 1.20 | -1.91 | -1.91 | 52.67 | 10.46 | 1.25 | -- | 5.56 | 207,970.60 | -4.45 | 0.4725 | -6.46 | 0.6678 | 13.86 | 12.18 | -3.58 | 0.4122 | -- | 1.17 | 0.5678 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
| Legend Biotech Corp (ADR) | 342.80m | -465.95m | 8.49bn | 1.80k | -- | 7.29 | -- | 24.76 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Data as of Jun 10 2024. Currency figures normalised to Cerevel Therapeutics Holdings Inc's reporting currency: US Dollar USD
25.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Mar 2024 | 10.79m | 5.95% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 7.56m | 4.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.25m | 3.99% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.88m | 2.69% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.53m | 1.94% |
| Fidelity Investments Canada ULCas of 31 Mar 2024 | 3.25m | 1.79% |
| Alpine Associates Management, Inc.as of 31 Mar 2024 | 2.34m | 1.29% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.33m | 1.28% |
| Pentwater Capital Management LPas of 31 Mar 2024 | 2.22m | 1.22% |
| Soros Fund Management LLCas of 31 Mar 2024 | 1.94m | 1.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
